AMIX AUTONOMIX MEDICAL INC

Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)

Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)

THE WOODLANDS, TX, April 03, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced an abstract detailing its technology and early proof-of-concept study results has been accepted for poster presentation at the , being held April 13-16, 2025 in Rotterdam, Netherlands.

Details of the poster presentation are as follows:

Title: Catheter-Based Transvascular RF Neural Ablation for Severe Pancreatic Cancer Pain: First Results from The Elpis Study

Authors: Robert S. Schwartz, MD, Chief Medical Officer of Autonomix Medical, Inc, and Askar Uktamovich Sabirov, MD, Primary Investigator, AKFA Medline Hospital

About ECIO 2025

The European Conference on Interventional Oncology (ECIO) is renowned as the most comprehensive platform for interventional oncology education and knowledge sharing - bringing together a growing community of experts from around the world for a multidisciplinary program covering all aspects of Interventional Oncology (IO). The conference will feature an outstanding line-up of more than 140 lectures and 16 hands-on training sessions, which will include highlights on topics such as immuno-oncology, revolutions in HCC treatment, pediatric IO, and much more.

For more information about the ECIO 2025 please visit the .

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with up to 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit and connect with the Company on , , and .

Investor and Media Contact

JTC Team, LLC

Jenene Thomas

833-475-8247



EN
03/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AUTONOMIX MEDICAL INC

 PRESS RELEASE

Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Con...

Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO) THE WOODLANDS, TX, April 03, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced an abstract detailing its technology and early proof-of-concept study results has been accepted for poster presentation at the , being held April 13-16, 2025 in Rotterdam, Netherlands. Details of the poster presen...

 PRESS RELEASE

Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listin...

Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) THE WOODLANDS, TX, March 21, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the Compensation Committee of Autonomix’s Board of Directors approved the grant of an inducement stock option on March 17, 2025 to purchase 7,500 shares of the Company’s common stock, to a new non-executive employee pursuant to ...

 PRESS RELEASE

Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Coll...

Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company’s Proprietary Catheter-Based Technology Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications  Proprietary sensing and ablation technology has demonstrated potential to more precisely target and eliminate overactive nerves, improving response rates and enhancing patient outcomes across multiple indications THE WOODLANDS, TX, March 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical devic...

 PRESS RELEASE

Autonomix Medical, Inc. Advances Toward U.S. Clinical Trials in 2025 w...

Autonomix Medical, Inc. Advances Toward U.S. Clinical Trials in 2025 with Completed Integration of Apex 6 Generator for Transvascular Ablation Company successfully meets key milestone with design lock that integrates and finalizes enhancements to its licensed Apex 6 Radiofrequency (“RF”) Generator On track for Investigational Device Exemption (“IDE”) submission and, if approved, U.S. clinical trial initiation in 2025 for pancreatic cancer pain Milestone advances proprietary sensing and ablation catheter technology into a fully integrated transvascular treatment platform THE WOODLANDS, TX...

 PRESS RELEASE

Autonomix Medical, Inc. Announces Abstract Highlighting Technology and...

Autonomix Medical, Inc. Announces Abstract Highlighting Technology and Early Proof-of-Concept Study Results Accepted at the Society of Interventional Radiology (SIR) Annual Scientific Meeting THE WOODLANDS, TX, March 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced its abstract has been accepted for poster presentation at the being held March 29-April 2, 2025 in in Nashville, Tennessee. Det...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch